Tofacitinib Ointment For Chronic Plaque Psoriasis

• Psoriasis Vulgaris
• Psoriasis

• Drug: tofacitinib ointment 20 mg/g
  
  tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
• Drug: tofacitinib ointment 10 mg/g
  
  tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
• Drug: placebo ointment (vehicle)
  
  placebo ointment (vehicle) BID (twice daily) for 12 weeks
• Drug: tofacitinib ointment 20 mg/g
  
  tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
• Drug: tofacitinib ointment 10 mg/g
  
  tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
• Drug: placebo ointment (vehicle)
  
  placebo ointment (vehicle) QD (once daily) for 12 weeks

• Experimental: Treatment Group A
  
  Intervention: Drug: tofacitinib ointment 20 mg/g
• Experimental: Treatment Group B
  
  Intervention: Drug: tofacitinib ointment 10 mg/g
• Placebo Comparator: Treatment Group C
  
  Intervention: Drug: placebo ointment (vehicle)
• Experimental: Treatment Group D
  
  Intervention: Drug: tofacitinib ointment 20 mg/g
• Experimental: Treatment Group E
  
  Intervention: Drug: tofacitinib ointment 10 mg/g
• Placebo Comparator: Treatment Group F
  
  Intervention: Drug: placebo ointment (vehicle)

Inclusion Criteria:

• Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline
• At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)
• If received certain treatments, should be off treatment for a minimum period of time (washout)

Exclusion Criteria:

• Currently have non-plaque forms of psoriasis or drug-induced psoriasis
• Require treatment with or cannot stop medication(s) prohibited during the study
• Have certain laboratory abnormalities at Baseline
• Current or history of certain infections
• Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception